GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gene Biotherapeutics Inc (OTCPK:CRXM) » Definitions » E10

Gene Biotherapeutics (Gene Biotherapeutics) E10 : $0.00 (As of Dec. 2020)


View and export this data going back to . Start your Free Trial

What is Gene Biotherapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Gene Biotherapeutics's adjusted earnings per share data for the three months ended in Dec. 2020 was $-0.017. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.00 for the trailing ten years ended in Dec. 2020.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-06-16), Gene Biotherapeutics's current stock price is $0.0001. Gene Biotherapeutics's E10 for the quarter that ended in Dec. 2020 was $0.00. Gene Biotherapeutics's Shiller PE Ratio of today is .


Gene Biotherapeutics E10 Historical Data

The historical data trend for Gene Biotherapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gene Biotherapeutics E10 Chart

Gene Biotherapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.01 - - - -

Gene Biotherapeutics Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Gene Biotherapeutics's E10

For the Biotechnology subindustry, Gene Biotherapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gene Biotherapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gene Biotherapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Gene Biotherapeutics's Shiller PE Ratio falls into.



Gene Biotherapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Gene Biotherapeutics's adjusted earnings per share data for the three months ended in Dec. 2020 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2020 (Change)*Current CPI (Dec. 2020)
=-0.017/109.8968*109.8968
=-0.017

Current CPI (Dec. 2020) = 109.8968.

Gene Biotherapeutics Quarterly Data

per share eps CPI Adj_EPS
200912 4.000 91.111 4.825
201003 -0.400 91.821 -0.479
201006 -0.200 91.962 -0.239
201009 -0.800 92.162 -0.954
201012 0.200 92.474 0.238
201103 -0.400 94.283 -0.466
201106 -0.400 95.235 -0.462
201109 -0.400 95.727 -0.459
201112 -0.400 95.213 -0.462
201203 -0.400 96.783 -0.454
201206 -0.310 96.819 -0.352
201209 -0.320 97.633 -0.360
201212 -0.310 96.871 -0.352
201303 -0.350 98.209 -0.392
201306 -0.370 98.518 -0.413
201309 -0.280 98.790 -0.311
201312 -0.340 98.326 -0.380
201403 -0.160 99.695 -0.176
201406 -0.090 100.560 -0.098
201409 -0.120 100.428 -0.131
201412 -0.140 99.070 -0.155
201503 -0.050 99.621 -0.055
201506 -0.110 100.684 -0.120
201509 -0.140 100.392 -0.153
201512 -0.040 99.792 -0.044
201603 -0.030 100.470 -0.033
201606 -0.050 101.688 -0.054
201609 -0.140 101.861 -0.151
201612 -0.070 101.863 -0.076
201703 -0.040 102.862 -0.043
201712 0.000 104.011 0.000
201812 0.000 105.998 0.000
201903 -0.020 107.251 -0.020
201906 -0.020 108.070 -0.020
201909 -0.010 108.329 -0.010
201912 0.090 108.420 0.091
202003 -0.010 108.902 -0.010
202006 0.004 108.767 0.004
202009 -0.015 109.815 -0.015
202012 -0.017 109.897 -0.017

Add all the adjusted EPS together and divide 10 will get our e10.


Gene Biotherapeutics  (OTCPK:CRXM) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Gene Biotherapeutics E10 Related Terms

Thank you for viewing the detailed overview of Gene Biotherapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Gene Biotherapeutics (Gene Biotherapeutics) Business Description

Traded in Other Exchanges
N/A
Address
11230 Sorrento Valley Road, Suite 220, San Diego, CA, USA, 92121
Gene Biotherapeutics Inc is a clinical stage biotechnology company focused on pre-clinical, clinical, and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The company's lead product candidate Generx is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.
Executives
Andrew M Leitch director 6615 CALLE PONTE BELLA, RANCHO SANTA FE CA 92091
Murray H Hutchison director C/O CADIZ INC., 550 SOUTH HOPE STREET, 2850, LOS ANGELES CA 90071
Dennis Mulroy officer: Chief Financial Officer
Ronald I Simon other: Former Director 485 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Robert N Weingarten director, officer: PRESIDENT and CFO 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367

Gene Biotherapeutics (Gene Biotherapeutics) Headlines